Streetbeat News

Stock Prices

INSM

Insmed Inc presented positive subgroup data from its Phase 3 ASPEN study on brensocatib for bronchiectasis at the CHEST 2024 Annual Meeting, showing consistency with overall trial results.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 8:07 pm

DKL

Delek Logistics Partners, LP (NYSE:DKL) announced a $150 million public offering of common units. The proceeds will be used to redeem convertible preferred units and repay borrowings. Executives have shown interest in purchasing units, but it's not binding.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 8:05 pm

CRDL

Cardiol Therapeutics Inc. (NASDAQ:CRDL) has filed a preliminary prospectus supplement for a proposed public offering of common shares. The company plans to use the proceeds to support clinical development and other expenses.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 8:03 pm

PRCT

Analysts have shown a predominantly bullish sentiment towards PROCEPT BioRobotics (NASDAQ:PRCT) over the past three months, with a notable increase in average price targets. The company's financials reveal strong revenue growth but challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 8:01 pm

BA

S&P has reported that Boeing will not meet its target of increasing the production of its Max planes to 38 per month by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 8:01 pm

GFS

GLOBALFOUNDRIES (NASDAQ:GFS) has received mixed analyst ratings over the past three months, with a decrease in the average 12-month price target from $62.83 to $56.83. Analysts have adjusted their ratings and price targets in response to market conditions, with some lowering their targets. The company faces financial challenges, including a decline in revenue growth and below-average net margin, ROE, and ROA compared to industry benchmarks.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 8:01 pm

WAT

Analysts have provided mixed ratings for Waters (NYSE:WAT) over the past three months, with a recent trend towards more bullish sentiments. The average 12-month price target has increased by 9.2% to $354.0. Despite revenue challenges, Waters shows strong profitability and financial management, though it carries a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 8:00 pm

PEN

Analysts have mixed views on Penumbra (NYSE:PEN) with recent ratings showing a decrease in average price targets. The company's financials reveal challenges in profitability and growth compared to industry peers.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 8:00 pm

PDCO

In the past three months, 6 analysts have provided ratings for Patterson Cos (NASDAQ:PDCO), with a mix of bullish and indifferent sentiments. The average 12-month price target has decreased from $27.50 to $25.33. Analysts have lowered their price targets, reflecting changing market dynamics and company performance. Patterson Cos faces challenges with a -2.22% revenue decline, but maintains strong net margins and effective debt management.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 8:00 pm

WMB

Williams Companies (NYSE:WMB) has delivered an impressive annualized return of 16.17% over the past 5 years, outperforming the market by 2.03%. A $1000 investment in WMB 5 years ago would now be worth $2,118.99, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 8:00 pm